LivaNova (LIVN) Q3 2026 earnings review
LivaNova raises its 2026 outlook again, but legal charges double
LivaNova's heart-surgery and epilepsy devices kept growing at a double-digit pace while legal provisions and factory spending weighed on reported profit and cash. Revenue rose 10% to $393 million, and chief executive Vladimir Makatsaria raised the full-year sales and adjusted profit outlook for a third straight quarter. By our math, the updated plan still points to sales growth slowing to about 7% in the fourth quarter.
| Revenue growth (excluding currency swings) | +10.0% $393.1M reported (+9.9% from a year ago) |
|---|---|
| Profit per share, excluding one-offs | $1.23 +10.8% from a year ago (reported GAAP: $0.11) |
| Full-year revenue growth outlook | Raised 1 pt 9%–10% excluding currency swings |
| Full-year profit per share outlook | Raised $0.10 $4.40–$4.50, excluding one-offs |
⚖️ Verdict: 🟢 Bullish
The story got better because LivaNova started production on its new oxygenator line on schedule and sped up epilepsy sales to 11% growth against a tougher comparison. Those two milestones address the main doubts about whether single-use surgical supplies and patient demand can carry growth in 2027. One caution: a $34 million legal charge for legacy heart-surgery machines cut reported operating profit nearly in half, and beating the prior second-half plan only proves management's outlook was cautious.
The question now is whether the new oxygenator line and sleep apnea billing codes translate into sustained 2027 growth and a recovery in cash flow. Optimists see the new factory line lifting surgical supply sales next year, while sceptics note that sleep apnea billing codes do not start until 2028 and legal and capital bills are still high. Management's initial 2027 outlook in February will settle the pace.
🐂 Bull Case
New Oxygenator Line Starts Running
LivaNova's cardiopulmonary division makes heart-lung machines and single-use oxygenators that add oxygen to a patient's blood during open-heart surgery. Demand for oxygenators has outrun what the company and its suppliers could make, and investors worried growth would slow once hospitals finished upgrading to its Essenz heart-lung machine in 2027.
This quarter LivaNova started operational production on a new oxygenator manufacturing line, "expanding production capacity to address strong customer demand". Cardiopulmonary sales rose 10.9% from a year ago to $225.3 million, with "growth across all regions, driven by strong consumables demand and Essenz™ Perfusion System sales, as well as favorable realized price".
The 10.9% gain came on top of an 18.0% jump in the same quarter last year, so the division kept growing fast despite a hard comparison. Having the new line running on schedule gives the medical device maker the extra single-use supply it needs to carry growth as machine upgrades level off.
What to watch: the initial 2027 cardiopulmonary sales outlook in February. A target near high-single-digit growth would show the new production line is picking up the slack from the maturing machine cycle.
Epilepsy Growth Accelerates on Volume and Price
The neuromodulation business sells VNS Therapy, an implanted device that sends mild pulses to the vagus nerve to reduce seizures in people with drug-resistant epilepsy. After US Medicare raised hospital payments for these procedures by nearly 50% in January, sceptics argued that higher prices were doing the work while patient numbers lagged.
Sales in the division grew 11.1% from a year ago to $166.1 million, or 11.2% excluding currency swings, with "growth across all regions, driven by higher volume and favorable realized price". In October, LivaNova also published 36-month results from its CORE-VNS clinical study showing "a 76% median reduction in seizure frequency and a durable clinical benefit".
Growth sped up for a third straight quarter — from 9.3% in the first quarter and 10.0% in the second — even though the year-ago period already included catch-up procedures. Both US sales (+10.4%) and international sales (+13.0% to +14.4%) rose at double-digit rates, showing that demand is broad-based.
What to watch: the promised breakdown of US epilepsy implant volumes on the fourth-quarter call. That disclosure will show how much of the gain comes from new patients rather than higher contract prices.
Third Outlook Raise Beat the Slowdown Plan
"Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies," chief executive Vladimir Makatsaria said. Three months ago, LivaNova's full-year plan pointed to second-half sales growth slowing to roughly 6% to 8% by our math, down from 12.5% in the first half.
Third-quarter revenue rose 9.9% to $393.1 million (10.8% by our math after stripping out a $3.1 million reserve release in last year's other revenue), beating that implied second-half pace. Makatsaria raised the full-year constant-currency sales outlook by one percentage point for a third straight quarter, to 9% to 10%, and lifted the profit per share outlook by $0.10 to $4.40 to $4.50.
Beating the implied second-half rate confirms that management sets cautious targets rather than facing a sudden drop in demand. Even after the raise, the new plan implies fourth-quarter sales growth of about 7.5% by our math.
What to watch: fourth-quarter constant-currency revenue growth against the implied 7.3% rate. Another beat would finish the year above 10% and set a higher base for 2027.
🐻 Bear Case
Legal Charges Cut Reported Profit in Half
LivaNova highlights operating profit excluding one-offs, which rose 14.8% to $92.3 million, lifting that margin by 1.0 percentage point to 23.5% of revenue. The improvement came from research and development spending excluding one-offs, which fell by 1.2 percentage points of revenue to 11.4%, while selling and administrative costs edged up 0.2 percentage points to 34.5%.
On a standard accounting basis, operating profit fell 47.4% from a year ago to $28.4 million, and the operating margin dropped 7.9 percentage points to 7.2%. Other operating expense jumped by 7.6 percentage points of revenue to $34.0 million for "3T Heater-Cooler litigation provision, and legal expenses primarily related to 3T Heater-Cooler defense", while legal and regulatory adjustments across all cost lines reached $39.8 million ($0.69 per share).
The 3T device is an older machine that regulates blood temperature during heart surgery and has drawn lawsuits for years. Treating these provisions as one-offs hides a recurring cash drain: LivaNova paid $12.9 million in 3T settlements this quarter and added $29.0 million to its litigation reserve over the first nine months.
What to watch: the remaining 3T claim count and reserve balance in the third-quarter filing. Another large provision would show that legal costs from legacy heart-surgery devices are still growing.
Convertible Debt Accounting Cuts Reported EPS
LivaNova has convertible notes due in 2029 that allow bondholders to exchange their debt for shares, alongside derivative contracts tied to those notes. Because the notes can turn into shares, accounting rules require the company to adjust both its share count and its reported profit when the value of that conversion option changes.
While basic net income rose 28.0% to $34.3 million ($0.62 per share), the diluted calculation subtracted a $28.2 million gain on the 2029 notes' conversion option and added 0.6 million convertible shares. That cut diluted net income to $6.1 million and pushed reported diluted profit per share down 77.6% to $0.11, while total diluted shares rose 4.0% from a year ago to 57.4 million.
On the company's preferred basis excluding one-offs, profit per share rose 10.8% to $1.23 because LivaNova strips out derivative swings. Still, the rising share count is real and Already exceeds the 56 million full-year average assumed in management's outlook.
What to watch: diluted share count in the fourth quarter and the 2027 share count assumption. Further increases above 57.4 million would slow per-share profit growth next year.
Factory Spending Keeps Cash Flow Below 2025
Last quarter LivaNova cut its full-year cash flow target by $20 million to pay for new oxygenator manufacturing equipment, information technology, and a component supply deal with Thermo Fisher. Investors are watching whether higher profit can offset that capital spending bill.
Third-quarter property and equipment purchases rose 34.5% from a year ago to $30.8 million (7.8% of revenue), bringing nine-month capital spending to $76.6 million against $48.8 million last year. As a result, operating cash flow fell 13.4% to $73.7 million and free cash flow excluding one-offs dropped 10.0% to $55.8 million.
- Q3 capital spending: $30.8 million, up from $22.9 million a year ago
- Nine-month free cash flow excluding one-offs: $105.1 million by our math, or 53.6% of adjusted net income
- Implied Q4 free cash flow excluding one-offs: $44.9 million at the $150 million outlook midpoint, down 16.1% from a year ago by our math
What to watch: the 2027 capital spending plan in February. A drop from this year's $135 million budget would show the factory expansion peak has passed and cash conversion can recover.
Sleep Apnea Device Wins Billing Codes
LivaNova aims to generate $200 million to $400 million in annual sales by 2030 from its aura6000 system, an implanted nerve stimulator for moderate to severe obstructive sleep apnea (when a patient's airway blocks during sleep). Last quarter, the regulatory filing for the commercial MRI-compatible version slipped from the second half of 2026 to a window stretching into the first half of 2027.
In October, the American Medical Association established new Category I billing codes that cover LivaNova's sleep apnea therapy, with an expected effective date of January 1, 2028. However, the third-quarter release gave no update on when LivaNova will submit the MRI device filing to the Food and Drug Administration or when commercial sales will begin.
Securing permanent billing codes for 2028 removes a reimbursement hurdle for hospitals and doctors. But because the codes do not take effect until 2028 and the device filing is still pending, the sleep apnea programme remains behind its earlier schedule.
What to watch: confirmation that LivaNova has submitted the MRI-compatible sleep apnea filing to the FDA. Any slip past the first half of 2027 would delay the commercial launch into 2028.
Risks This Quarter Didn't Answer
Several standing risks and product programmes received no update in the third-quarter earnings release because LivaNova gives those details on its conference call or in its quarterly filing.
- SNIA environmental liability: the balance sheet still carries a $383.6 million current liability for legacy Italian chemical waste with no cash paid in the first nine months; the December 9, 2026 settlement hearing will test the payout amount and timing.
- Depression therapy coverage: the release did not mention discussions with US Medicare to cover VNS Therapy for difficult-to-treat depression; a coverage decision remains necessary before sales can move beyond roughly $10 million a year.
- Segment growth targets and Essenz share: updated full-year growth ranges for Cardiopulmonary and Epilepsy and the 80% Essenz placement share target were not in the release tables; the conference call remarks will show how the 1-point revenue raise splits between the two divisions.
💲 Other KPIs
Cash exceeded carrying debt by $264.4 million on September 30, up from $223.1 million three months ago by our math. Over the first nine months, LivaNova repaid $95.9 million of long-term debt and paid $50.4 million of contingent consideration — milestone payouts for its past ImThera sleep apnea acquisition — ending the quarter with $563.5 million in cash.
Customer bills owed to the British medical device group rose 9.4% from year-end to $236.4 million, while inventories grew 8.0% to $177.9 million as the new oxygenator line stocked up. Together, those two working-capital lines tied up $37.9 million of operating cash over the first nine months, compared with $13.9 million a year ago.
🔮 Guidance
Raised. Management lifted its full-year sales growth plan excluding currency swings by 1 percentage point, to 9.5% at the middle of the range. It is the third consecutive 1-point raise this year: +1.0 pt in Q1, +1.0 pt in Q2, +1.0 pt in Q3. By our math, after 10.3% growth in the first nine months, the plan leaves about 7.3% growth for the fourth quarter.
Unchanged. Currency exchange rates are still expected to add about 1 percentage point to reported full-year sales growth, bringing the middle of the reported growth range to 10.5% by our math. Because currency added 1.3 percentage points over the first nine months and subtracted 0.1 points in the third quarter, the plan assumes little currency help in the fourth quarter.
Raised. LivaNova lifted its full-year profit per share forecast by $0.10 at the middle of the range to $4.45, or 14.1% growth from last year by our math. It is the third raise this year: +$0.05, +$0.10, +$0.10. By our math, subtracting $3.48 earned in the first nine months leaves $0.97 for the fourth quarter, up 12.8% from $0.86 a year ago.
Unchanged. The full-year cash flow target stays at $150 million at the middle of the range, down 18.2% from last year's $183.3 million after the company cut the range by $20 million last quarter for factory spending. By our math, after generating $105.1 million in the first nine months, the plan leaves $44.9 million for the fourth quarter, down 16.1% from $53.5 million a year ago.
❓ Key Questions
When will LivaNova file the commercial sleep apnea device?
The release highlighted new 2028 billing codes for sleep apnea but gave no date for the MRI-compatible FDA filing that slipped last quarter. Any further delay pushes commercial revenue closer to the 2030 target date.
What drove the $34 million 3T litigation charge?
Other operating expense for 3T Heater-Cooler legal provisions jumped to $34.0 million in Q3 from $12.4 million in H1. Investors need to know how many claims remain and when cash payouts will end.
How much of US epilepsy growth came from patient volume?
Neuromodulation sales accelerated to 11.1% growth on higher volume and Medicare price increases, but LivaNova still does not publish implant counts. Separating volume from price shows how much growth carries into 2027 after the price step laps.
What is the status of the December SNIA court hearing?
LivaNova carries a $383.6 million current liability for the Italian SNIA environmental case and has paid nothing out this year. The December 9 settlement hearing will determine when that cash leaves the balance sheet.